Therapeutic modalities that improve -cell function are considered critical to T2DM management
Even modest resistance trainingusing body weight, resistance bands, or light weightsdemonstrates benefit
These milestones highlight the growing regulatory and clinical momentum supporting expanded uses Ongoing trials are also exploring the impact of GLP-1 agonists on cardiovascular outcomes, liver health, and even neurodegenerative diseases, reinforcing their value in treating systemic metabolic disorders
Due to lower levels of endogenous antioxidants, the brain is also more susceptible to oxidative stress
Injectable medications like semaglutide (injectable) are not affected by that binding but GI side effects may overlap
The GIP Receptor Pathway Glucose-dependent insulinotropic polypeptide (GIP) is another gut hormone that Tirzepatide targets